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POLYGLANDULAR	ENDOCRINOPATHY	TYPE	II	(SCHMIDT’S	SYNDROME)	IN	A	DOBERMAN	PINSCHER	1	
Abstract	2	
A	 3-year-old,	 female	 neutered,	 Doberman	 pinscher	 was	 presented	 for	 investigation	 of	 lethargy,	3	
episodic	 collapse,	 ataxia	 and	 myxoedema.	 Primary	 hypothyroidism	 and	 primary	 cortisol	 deficient	4	
hypoadrenocorticism	 were	 diagnosed	 based	 on	 history,	 physical	 examination	 and	 compatible	5	
hormonal	 analysis.	 Increased	 serum	 concentrations	 of	 thyroglobulin	 autoantibodies	 and	 21-6	
hydroxylase	autoantibodies	indicated	an	immune-mediated	aetiology.	The	case	was	complicated	by	7	
lymphadenopathy	with	hand-mirror	 lymphocytes,	classically	 identified	in	 lymphoma.	A	PCR	test	for	8	
antigen	 receptor	 rearrangement	 (PPAR	 test)	 indicated	 polyclonality	 and	 therefore	 reactive	9	
lymphadenopathy.	 The	 dog’s	 clinical	 signs	 resolved	 following	 introduction	 of	 levothyroxine	 and	10	
prednisolone.	 Prioritising	 the	 problem-based	 approach	 in	 this	 case	 facilitated	 the	 diagnosis	 of	11	
hypoadrenocorticism	 in	addition	 to	hypothyroidism	due	 to	 the	persistence	of	 clinical	 signs	despite	12	
thyroxine	 replacement.	 Importantly,	 atypical	 adrenal	 gland	 dysfunction	was	 not	misinterpreted	 as	13	
inadequate	therapeutic	response	to	thyroxine	supplementation.	The	observation	that	polyglandular	14	
endocrinopathy	 type	 II	 can	 occur	 in	 dogs	 suggests	 that	 in	 dogs	 with	 a	 suboptimal	 response	 to	15	
treatment	 for	 hypothyroidism	 or	 hypoadrenocorticism	 comorbid	 endocrinopathies	 should	 be	16	
investigated.	17	
Introduction	18	
Comorbid	 endocrinopathies	 are	 rare	 in	 dogs	 and	polyglandular	 autoimmune	endocrinopathies	 are	19	
even	 less	 common.	 The	 most	 frequently	 reported	 comorbid	 endocrinopathies	 are	20	
hyperadrenocorticism	and	diabetes	mellitus,	however	this	combination	is	not	autoimmune	(Peterson	21	
et	al	1981).	A	recent	case	series	reported	2.3%	of	dogs	admitted	to	a	referral	clinic	with	endocrine	22	
disease	had	 comorbid	endocrinopathies	 (Blois	et	al	 2011).	Of	 these,	 7	 (20%)	were	diagnosed	with	23	
hypothyroidism	 and	 hypoadrenocorticism	 (4	 of	 which	 had	 glucocorticoid	 deficient	24	
hypoadrenocorticism,	though	aldosterone	concentrations	were	not	reported),	however	this	study	did	25	
not	report	whether	these	cases	were	autoimmune.	Other	than	this	series,	comorbid	hypothyroidism	26	
and	glucocorticoid	deficient	hypoadrenocorticism	has	been	reported	as	an	isolated	case	report	in	a	27	
Boxer	 (Kooistra	 et	 al	 1995).	 Another	 dog	 is	 reported	 with	 typical	 hypoadrenocorticism	28	
(mineralocorticoid	and	glucocorticoid	deficiencies)	in	addition	to	hypothyroidism	(Pikula	et	al	2007).	29	
To	 date	 none	 of	 the	 reports	 of	 comorbid	 hypothyroidism	 and	 glucocorticoid	 deficient	30	
hypoadrenocorticism	have	demonstrated	immune	mediated	adrenalitis.	This	report	describes	a	dog	31	
with	comorbid	endocrine	disease,	similar	to	Schmidt’s	syndrome,	the	type-II	polyglandular	syndrome	32	
described	 in	 humans.	 The	 report	 presents	 serological	 evidence	 for	 immune-mediated	 adrenalitis,	33	
comparable	to	the	situation	often	identified	human	cases.	Schmidt’s	syndrome	is	the	most	common	34	
(poly)immunoendocrinopathy	 in	 humans,	 characterised	 by	 both	 autoimmune	 adrenalitis	 and	35	
thyroiditis	and/or	type	I	diabetes	mellitus	(Gupta	and	Nagri	2012).		36	
	37	
Case	history	38	
A	3-year-old	female	neutered	Doberman	pinscher	was	referred	due	to	progressive	weight	gain,	poor	39	
coat	condition	and	lethargy	for	6	weeks.	Over	the	past	week	she	had	developed	polydipsia,	generalised	40	
weakness	and	episodic	collapse.	On	examination	she	was	depressed	and	had	a	high	body	condition	41	
score	7/9.	She	was	hypothermic	(rectal	temperature	35.9°C)	with	tacky	oral	mucous	membranes	and	42	
a	relative	bradycardia	(44bpm)	with	poor	peripheral	pulse	quality.	She	had	myxoedema	of	the	head,	43	
a	brittle	hair	coat,	pinna	margin	crusting	and	thickened	skin.	She	had	submandibular,	prescapular	and	44	
popliteal	 lymphadenopathy.	 Thoracic	 and	 cardiac	 auscultations	 and	 abdominal	 palpation	 were	45	
unremarkable.	Neurological	examination	revealed	mild	ataxia	and	reduced	conscious	proprioception	46	
with	retained	spinal	reflexes.		47	
Following	 admission,	 the	 dog	 was	 actively	 warmed	 and	 provided	 with	 intravenous	 fluid	 support.	48	
Serum	biochemistry	and	complete	blood	count	were	performed	(Table	1).	These	revealed	an	equivocal	49	
increase	 in	 alanine	 aminotransferase	 and	 creatinine	 kinase,	 a	 mild	 azotaemia,	 a	 mild	 increase	 in	50	
cholesterol	 and	 triglyceride	 concentrations	 along	 with	 non-regenerative	 anaemia.	 Electro	 and	51	
echocardiograms	were	both	unremarkable.	A	strong	clinical	suspicion	for	hypothyroidism	meant	total	52	
thyroxine	 and	 thyroid	 stimulating	 hormone	 (TSH)	 concentrations	 were	 measured.	 Reduced	 total	53	
thyroxine	 and	 increased	 TSH	 concentrations	 indicated	 primary	 hypothyroidism	 (Nelson	 1991).	 An	54	
increase	in	thyroglobulin	autoantibody	concentrations	confirmed	immune-mediated	thyroiditis	(Table	55	
2).	The	myxoedema	and	demeanour	improved	within	48	hours	of	initiating	levothyroxinea.	Despite	the	56	
improvement,	 the	 generalised	weakness	 and	 lymphadenopathy	 persisted.	 Given	 the	 absence	 of	 a	57	
stress	leucogram	and	persistent	weakness,	resting	cortisol	concentration	was	measured	and	the	result	58	
did	not	 exclude	hypoadrenocorticism	 (Table	 2).	Adrenal	 function	 testing	was	 therefore	performed	59	
using	 an	 adrenocorticotrophic	 hormone	 (ACTH)	 stimulation	 test,	 which	 confirmed	60	
hypoadrenocorticism	(Table	2).	A	normal	aldosterone	response	at	60	minutes	post-ACTH	stimulation,	61	
normal	serum	electrolytes,	normal	renin	concentration	and	increased	ACTH	concentration,	suggested	62	
primary	 cortisol	 deficient	 hypoadrenocorticism	 (Feldman	 2004	 and	 Thompson	 et	 al	 2007).	 An	63	
increased	 serum	 concentration	 of	 21-hydroxylase	 autoantibodies	 (21-OHAb)	 suggested	 immune-64	
mediated	adrenalitis	(Rick	et	al	2013).	Glucocorticoid	replacement	(prednisolone	0.25mg/kg	PO	SID)	65	
normalised	the	dog’s	demeanour	and	the	weakness	resolved	within	24	hours;	there	were	no	further	66	
episodes	of	collapse.	67	
Due	to	persistent	peripheral	lymphadenopathy,	fine	needle	aspirates	were	obtained.	These	revealed	68	
small	 homogenous	 hand-mirror	 lymphocytes	 suspicious	 for	 lymphoma	 (Zaharopoulos	 et	 al	 1990).	69	
Thoracic	radiographs	and	abdominal	ultrasound	were	unremarkable;	aspirates	of	the	liver	and	spleen	70	
revealed	no	evidence	 for	mirror-handle	 lymphocytes.	A	polymerase	chain	reaction	test	 for	antigen	71	
receptor	rearrangement	(PARR	test)	was	performed	on	the	lymph	node	aspirates	(Pate	et	al	2011).	72	
This	revealed	polyclonality,	consistent	with	lymph	node	hyperplasia	not	neoplasia.	73	
A	 final	 diagnosis	 of	 autoimmune	 polyglandular	 disease	was	made,	 akin	 to	 Schmidt’s	 syndrome	 in	74	
people	(Gupta	and	Nagri	2012	and	Neufeld	et	al	1990),	with	concomitant	lymph	node	hyperplasia.		75	
The	clinical	signs	and	the	lymphadenopathy	resolved	within	a	week	of	discharge.	After	4	weeks,	the	76	
dog’s	 body	 condition	 score	 had	 improved.	 The	 dog	was	 brighter,	 the	 dermatological	 changes	 had	77	
improved	and	the	reminder	of	the	clinical	examination	was	unremarkable.	Biochemistry	revealed	a	78	
mild	 improvement	 in	 the	 cholesterol	 (Table	 3),	 a	mild	 increase	 in	ALT	 and	ALP	were	 likely	 due	 to	79	
metabolic	 hepatopathy.	 At	 the	 time	 of	 writing,	 3	 years	 post-diagnosis,	 the	 dog	 remains	 well	 and	80	
continues	 to	 receive	 thyroid	 and	 glucocorticoid	 replacement.	 No	 electrolyte	 abnormalities	 have	81	
developed	 to	 suggest	 development	 of	 overt	 mineralocorticoid	 deficiency	 or	 hyperglycaemia	 to	82	
suggest	diabetes	mellitus.	83	
Discussion	84	
Polyglandular	endocrinopathies	are	uncommon	in	people	and	dogs	(Betterle	et	al	2004	and	Blois	et	al	85	
2011).	A	canine	case	series	by	Blois	et	al	(2011),	suggested	hypothyroidism	and	hypoadrenocorticism	86	
was	the	second	most	common	combination	after	hyperadrenocorticism	and	diabetes	mellitus.	As	seen	87	
in	this	case,	glucocorticoid	deficient	hypoadrenocorticism	can	be	challenging	to	diagnose	due	to	the	88	
absence	of	pathognomonic	signs	and	insidious	disease	progression;	there	is	still	controversy	regarding	89	
appropriate	screening	in	humans	(Cutolo	2014).	Baumstark	et	al	(JVIM	2014)	demonstrated	that	the	90	
majority	 of	 dogs	 diagnosed	 with	 primary	 hypoadrenocorticism	 with	 unremarkable	 electrolyte	91	
concentrations	 do	 have	 aldosterone	 deficiency.	 In	 this	 case,	 aldosterone	 concentration	 did	 rise	92	
following	ACTH	administration	and	plasma	renin	was	not	elevated	 indicating	true	 isolated	cortisol-93	
deficient	hypoadrenocorticism.	In	this	case,	as	with	previous	reports,	hypothyroidism	was	diagnosed	94	
first	followed	by	hypoadrenocorticism	(Kooistra	et	al	2008	and	Pikula	et	al	2007).	However,	compared	95	
to	previous	reports,	this	dog	had	both	endocrinopathies	identified	within	72	hours.	By	contrast,	the	96	
first	endocrinopathy	identified	in	humans	is	typically	hypoadrenocorticism	(Gupta	and	Nagri	2012).	It	97	
has	been	reported	that	initiating	thyroxine	replacement	in	Schmidt’s	syndrome	prior	to	glucocorticoid	98	
replacement	can	precipitate	an	adrenal	crisis	due	to	enhanced	hepatic	corticosteroid	metabolism	and	99	
a	general	increase	in	metabolic	rate	(Betterle	et	al	2004).	Despite	the	introduction	of	levothyroxine	in	100	
this	case	prior	to	glucocorticoid	replacement,	an	adrenal	crisis	was	not	observed,	possibly	due	to	the	101	
short	 interval	 between	 introducing	 supplementation.	 It	 is	 possible	 that	 this	 dog	would	 have	 been	102	
discharged	and	suffered	an	acute	adrenal	crisis	pending	a	review	of	her	thyroid	disease	without	further	103	
investigations	 if	 additional	 differentials	 for	 her	 persistent	 lethargy	 and	 collapse	 had	 not	 been	104	
considered.	In	people,	subclinical	polyglandular	disease	is	often	overlooked,	as	polyglandular	function	105	
testing	is	rarely	performed	at	the	time	of	initial	presentation	(Betterle	et	al	2004).	106	
Schmidt’s	 syndrome	 in	 humans	 is	 an	 autoimmune	 condition	 (Betterle	 et	 al	 2004).	 In	 this	 dog	107	
measurement	 of	 21-OHAb	 and	 anti-thyroglobulin	 antibody	 concentrations	 confirmed	 a	 similar	108	
aetiology.	21-OHAb	have	been	identified	in	30%	of	dogs	with	hypoadrenocorticism,	with	a	specificity	109	
of	95%	(Rick	et	al	2013).	In	this	case,	the	increase	in	21-OHAb	in	conjunction	with	compatible	clinical	110	
findings	 and	 biochemical	 results	 provided	 strong	 evidence	 for	 autoimmune	 adrenalitis.	 This	 is	111	
consistent	with	their	use	in	humans	(Betterle	et	al	2005).	As	with	anti-thyroglobulin	autoantibodies	in	112	
dogs,	a	cohort	of	humans	have	circulating	21-OHAb	in	the	absence	of	adrenal	insufficiency	(Betterle	113	
et	al	2005).	The	frequency	with	which	21-OHAb	occur	in	a	larger	cohort	of	normal	dogs	remains	to	be	114	
determined	 (Kooistra	et	 al	 1995,	 Pikula	et	 al	 2007,	 Rick	et	 al	 2013).	 In	 addition	 to	 direct	 immune	115	
mediated	destruction	of	the	thyroid	and	adrenal	glands	in	canine	Schmidt’s	syndrome,	 lymphocytic	116	
adenohypophysitis	has	also	been	reported	(Adissu	et	al	2010).	This	seemed	unlikely	in	this	case	due	117	
to	elevated	concentrations	of	both	ACTH	and	TSH.	Diabetes	mellitus	(DM)	is	present	 in	a	subset	of	118	
humans	with	Schmidt’s	syndrome,	however	was	not	encountered	in	this	dog	at	any	point	(Gupta	and	119	
Nagri	2012	and	Betterle	et	al	2004).	 Interestingly,	humans	may	also	have	antibodies	 to	pancreatic	120	
antigens	but	never	develop	overt	DM;	these	have	not	been	measured	in	this	dog	at	the	time	of	writing.		121	
The	dog’s	azotaemia	was	suspected	to	result	from	a	combination	of	hypovolaemia	and	reduced	GFR	122	
due	 to	 the	hypothyroidism	 (Panciera	 and	 Lefebvre	 2009).	 Intravenous	 fluid	 therapy	 and	 thyroxine	123	
replacement	are	 likely	 to	have	both	contributed	 to	normalisation	prior	 to	discharge	and	sustained	124	
resolution	of	the	azotaemia.	Unfortunately	this	cannot	be	verified	in	the	absence	of	a	urinalysis	at	the	125	
time	of	arrival	126	
Hand-mirror	lymphocytes	result	from	intracellular	incorporation	of	immune-complexes	(McGraw	et	al	127	
1981,	 Zaharopouls	 et	 al	 1990).	 Most	 references	 to	 hand-mirror	 lymphocytes	 relate	 to	128	
lymphoproliferative	disease	(Schumacher	et	al	1978	and	Thomas	et	al	1980),	however	these	are	also	129	
seen	during	cell	migration	and	immune	stimulation	(Biberfeld	et	al	1970	and	Hyun	et	al	2012).	There	130	
are	 however	 no	 reports	 of	 lymphadenopathy	 with	 hand-mirror	 lymphocytes	 in	 association	 with	131	
endocrinopathies.	 In	 this	 dog	 we	 suspect	 they	 were	 secondary	 to	 immune-mediated	 disease	 (as	132	
demonstrated	 by	 the	 elevated	 TGAA	 and	 21-OHb).	 Future	 investigations	 into	 the	 lymphoid	133	
populations	in	dogs	with	comorbid	endocrinopathies	would	clarify	this	point.		134	
	135	
This	 case	 emphasises	 the	 importance	 of	 a	 systematic	 clinical	 approach	 based	 on	 problems	 and	136	
differentials	and	cautions	against	pattern	recognition	as	a	sole	means	of	directing	diagnostic	testing.	137	
Should	this	approach	not	have	been	followed	in	this	case,	the	hypoadrenocorticism	would	have	been	138	
missed	 and	 the	 dog’s	 condition	 could	 have	 worsened	 due	 to	 the	 introduction	 of	 thyroxine	 and	139	
precipitation	of	an	adrenal	crisis.	It	emphasises	the	value	of	screening	for	concurrent	endocrinopathies	140	
in	 dogs	 where	 clinical	 abnormalities	 persist.	 This	 is	 particularly	 significant	 due	 to	 the	 increasing	141	
frequency	 with	 which	 glucocorticoid	 deficient	 hypoadrenocorticism	 is	 being	 recognised	 in	 dogs	142	
presenting	with	normal	electrolyte	 concentrations	 (Behrend	and	Kennis	2010	and	Baumstark	et	al	143	
2014).		144	
Footnote	145	
	146	
1	0.02mg/kg	PO	q12hrs,	Thyforon,	Dechra	(manufacturer	has	subsequently	replaced	with	Forthyron)			147	
	148	
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Table	1:	Biochemistry	and	Haematology	
Biochemistry	
Test	 Result	 Reference	range	
Total	protein															 73										g/L													 (54.0	-77.0	)	
Albumin			 32										g/L													 	(26.0	-40.0	)	
Globulin									 41										g/L													 (20.0	-47.0	)	
Sodium				 143									mmol/L										 (139		-154		)	
Potassium			 	5.2									mmol/L										 (3.5		-6.0		)	
Na:K	ratio																		 28											 (25.0	-35.0	)	
Chloride	 107									mmol/L										 (99			-125	)	
Total	calcium															 2.58								mmol/L										 (2.0		-3.0		)	
Phosphate					 1.40								mmol/L										 	(0.8		-1.6		)	
Urea	 *	9.8									mmol/L					 	(2.0		-9.0		)	
Creatinine	 *	156									umol/L					 (40.0	-106.0)	
ALP																				 12										U/L													 (0.0		-25.0	)	
ALT						 *	77										U/L								 (0.0		-25.0	)	
GLDH	 5											U/L													 (0.0		-10.0	)	
Total	bilirubin													 1											umol/L										 (0		-	9.0	)	
Bile	acids																		 1											umol/L										 (0		-	10.0	)	
Glucose	 3.49									mmol/L	 (3	-	7)	
CK																 *	376									U/L								 (0.0		-190.0)	
Cholesterol			 *	8.6									mmol/L										 (3.8		-7.0		)	
Triglycerides	 *	3.8									mmol/L										 (0.45	-1.9		)	
Amylase			 1616								U/L													 (0.0		-1800.0)	
Lipase			 49										U/L													 (0.0		-	150.0)	
	
Haematology	
RBC															 *	4.05								x10^12/L			 	(5.0		-8.5		)	
Hb												 *	10.0								g/dl							 (12.0	-18.0	)	
HCT									 *	29.5								%										 (37.0	-55.0	)	
MCV																				 72.8								fl														 (60.0	-80.0	)	
MCH	 24.7								pg														 (19.0	-26.0	)	
MCHC	 33.9								g/dl												 (31.5	-37.0	)	
Platelets					 311									x10^9/L									 (160		-500		)	
WBC	 7.10								x10^9/L									 (6.0		-15.0	)	
Neutrophils			 5.68								x10^9/L									 (3.0		-11.5	)	
Bands	 0.14								x10^9/L									 (0.0		-0.3		)	
Lymphocytes	 *	0.99								x10^9/L				 (1.0		-4.8		)	
Monocytes					 0.14								x10^9/L									 (0.0		-1.3		)	
Eosinophils			 0.14								x10^9/L									 (0.0		-1.25	)	
	
	
	
	
	
	
	
Table	2:	Endocrine	testing	
Test							 Result	 Reference	Range	
Thyroxine	(Microgenics)		 7.5							Low						nmol/L				 13.0	-	51.0	
Free	T4	(equilibrium	dialysis	RIA)							*	<2.0									pmol/l							 7	-	40									
Canine	Serum	TSH													 1.06						High					ng/mL						 0.00	-	0.50	
	
Thyroid	antiglobulin	antibody												 *	716										%												 <200					
Adrenal	Axis	Testing	
Cortisol	Basal	(RIA)																					 *	<20										nmol/l	 28	-	250	
Cortisol	post	ACTH	(RIA)																	 *	<20										nmol/l							 200	-	400	
21-Hydroxylase	(optical	density	measurement)			0.224	(hypoadrenocorticism	>0.2)	
Aldosterone	 126	pmol/l	 0	-	960	
Aldosterone	post	ACTH	(RIA)	 326	pmol/l		 200	-	2100	
Endogenous	ACTH	Assay																				 *	104										pg/ml								 20	-	80		
Plasma	Renin																															 1.85									ng/mL/hr					 0.22	-	2.4					
RIA:	Radioimmunoassay	
	
Table	3:	Biochemistry	(4	weeks	post	start	of	therapy)	
Biochemistry	(4weeks	after	thyroid	supplementation	and	prednisolone)	
Test	 Result	 Reference	range	
Total	protein															 76										g/L													 (54.0	-77.0	)	
Albumin			 39										g/L													 	(26.0	-40.0	)	
Globulin									 37										g/L													 (20.0	-47.0	)	
Sodium				 144									mmol/L										 (139		-154		)	
Potassium			 	4.6									mmol/L										 (3.5		-6.0		)	
Na:K	ratio																		 31										 (25.0	-35.0	)	
Chloride	 104								mmol/L										 (99			-125	)	
Total	calcium															 2.80								mmol/L										 (2.0		-3.0		)	
Phosphate					 *	2.00								mmol/L										 	(0.8		-1.6		)	
Urea	 8.9									mmol/L					 (2.0		-9.0		)	
Creatinine	 94									umol/L					 (40.0	-106.0)	
ALP																				 *66									U/L													 	(0.0		-25.0	)	
ALT						 *	35									U/L								 (0.0		-25.0	)	
GLDH	 4											U/L													 (0.0		-10.0	)	
Total	bilirubin													 2										umol/L										 (0		-	9.0	)	
Bile	acids																		 3											umol/L										 (0		-	10.0	)	
CK																 132									U/L								 	(0.0		-190.0)	
Cholesterol			 *	7.3									mmol/L										 (3.8		-7.0		)	
Triglycerides	 *	3.8									mmol/L										 (0.45	-1.9		)	
Amylase			 1616								U/L													 (0.0		-1800.0)	
Lipase			 49										U/L													 (0.0		-	150.0)	
	
	
	
	
